Carregant...
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). Novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms o...
Guardat en:
| Publicat a: | Clin Pharmacol Ther |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715745/ https://ncbi.nlm.nih.gov/pubmed/26331358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.256 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|